Patents Examined by Garen Gotfredson
  • Patent number: 11052556
    Abstract: A liquid dispensing razor including a reservoir containing a shave care composition. The shave care composition comprises water; one or more lipophilic skin conditioning agents; one or more thickening agents including electrolyte sensitive polymers; one or more emulsifying agents; and one or more lubricants. The shave care composition is delivered to the skin by the razor to provide skin comfort and moisturization benefits during the shave. The combination of the chemistry in the razor results in step change in skin condition in consumer and technical skin moisturization benefits.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: July 6, 2021
    Assignee: The Gillette Company LLC
    Inventors: Timothy Coffindaffer, Benjamin P Heath, Kenneth E Kyte, Katharine A Bakes, Joseph A DePuydt
  • Patent number: 11020401
    Abstract: A composition for human consumption includes a base composition having a pH of about 2 to about 5 and encapsulated caffeine dispersed throughout at least a portion of the base composition. The encapsulated caffeine can be a caffeine complex. The base composition can include a liquid or a food. An oral pouch product includes a porous pouch wrapper, an inner botanical filling material contained within the pouch wrapper, and encapsulated caffeine dispersed throughout at least a portion of the oral pouch product. The encapsulated caffeine is included in the composition and/or the oral pouch product an amount sufficient to release about 50 mg to about 200 mg of caffeine. The composition can provide immediate release of caffeine and/or release of caffeine over an extended period of time.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: June 1, 2021
    Assignee: Altria Client Services LLC
    Inventors: Munmaya K. Mishra, Gerd Kobal
  • Patent number: 11013707
    Abstract: Methods of administering methyldopa to a subject in a fasting state to increase bioavailability of the methyldopa.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 25, 2021
    Assignees: The Regents of the University of Colorado, a body corporate, ImmunoMolecular Therapeutics, Inc.
    Inventors: Steve Orndorff, Aaron Michels
  • Patent number: 11013684
    Abstract: A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 25, 2021
    Assignee: AQIX, Ltd.
    Inventor: Douglas Rees
  • Patent number: 10988600
    Abstract: A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more cyclodextrin molecules, and further comprising a guest molecule capable of forming a guest-host complex with the aminocyclodextrin molecule acting as a host, wherein the guest molecule is a retinoid, preferably adapalene, or a RAM BA. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: April 27, 2021
    Assignee: GALDERMA HOLDING SA
    Inventors: Katarina Edsman, Jean-Guy Boiteau
  • Patent number: 10987310
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: April 27, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Patent number: 10973768
    Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: April 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
  • Patent number: 10973868
    Abstract: The present disclosure relates to a composition comprising a carnosine-magnesium complex. The composition is designed to be applied to the skin and causes an increase in carnosine levels in the body. The topical 5 composition comprising a carnosine-magnesium complex has the effect of improving an athlete's physical performance and may be effective for the treatment of a variety of medical conditions. Also disclosed is a method for preparing the carnosine-magnesium complex.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 13, 2021
    Inventors: Chad Macias, Tim Sharpe, Massimo Ferrari
  • Patent number: 10967063
    Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or more other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: April 6, 2021
    Assignee: Vyne Therapeutics Inc.
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Patent number: 10966931
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 6, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Patent number: 10959956
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 30, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Patent number: 10933140
    Abstract: Hydrogels and hybrid hydrogels, methods of making the hydrogels/hybrid hydrogels, and methods of using the hydrogels/hybrid hydrogels. The hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties). The hybrid hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties) and poly(ester amide) moieties. The poly(ester amide) moieties can have one or more arginine moieties. The hydrogels/hybrid hydrogels can be used, for example, in consumer products and as cargo carrier materials (e.g., as therapeutic agent carriers).
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: March 2, 2021
    Assignee: Cornell University
    Inventors: Chih-Chang Chu, DeQun Wu, Mingyu He
  • Patent number: 10918607
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: February 16, 2021
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
  • Patent number: 10912794
    Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 9, 2021
    Assignee: KEMIN INDUSTRIES, INC.
    Inventors: Geoffrey Paul Horst, Robert Bernard Levine
  • Patent number: 10912739
    Abstract: The present technology relates generally to devices for treatment of skin and skin conditions, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and one or more active agents, wherein the amount of the active agent(s) does not reduce the absorption properties of the hydrocolloid dressing.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: February 9, 2021
    Assignee: PEACE OUT INC.
    Inventor: Enrico Frezza
  • Patent number: 10874618
    Abstract: The invention relates to a new fixed dose combination of benazepril with pimobendan.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 29, 2020
    Assignee: Elanco Tiergesundheit AG
    Inventors: Jernej Grmas, Zdenka Jerala-Strukelj, Sebastjan Reven
  • Patent number: 10875772
    Abstract: A hydrogel comprising a colloidal suspension of MIXMIIYPZ two-dimensional nanocrystals in water, wherein MI is Na+ and/or Li+, MII is Mg2+ or a mixture of Mg2+ with one or more Ni2+, Zn2+, Cu2+, Fe2+ and/or Mn2+, P is a mixture of dibasic phosphate ions (HPO42?) and tribasic phosphate ions (PO43?), X ranges from about 0.43 to about 0.63, Y ranges from about 0.10 to about 0.18, Z ranges from about 0.29 to about 0.48, X, Y, Z being mole fractions, is provided.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: December 29, 2020
    Assignee: INVICARE INC.
    Inventors: Faleh Tamimi Marino, Ashwaq Ali Al-Hashedi, Marco Laurenti, Ahmed Ebraheem Al Subaie, Mohamed-Nur Abdallah, Iskandar Tamimi Marino
  • Patent number: 10849839
    Abstract: A personal care formulation comprising an active compound is operable to reduce the surface friction of hair fibres and promoting inter-fibre movement. The active compound is the reaction product of a fatty acid and a polyamine. The use of the active compound in a personal care formulation works as a friction modifier operable to reduce the surface friction of hair fibres. The invention extends to the active compound and a method of reducing hair-fibre surface friction.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: December 1, 2020
    Assignee: Croda International Plc
    Inventors: Michael Christopher Hindley, David John Freeman, James Prodger, Sean Philip Nigel Rouse
  • Patent number: 10828246
    Abstract: This disclosure relates to hair styling compositions and processes, and more particularly to compositions for disentangling or crosslinking hair that are useful in hair styling processes.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 10, 2020
    Assignee: NUtech Ventures
    Inventors: Yiqi Yang, Helan Xu, Kaili Song
  • Patent number: 10813885
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 27, 2020
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer